Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans.

Fraher LJ, Klein K, Marier R, Freeman D, Hendy GN, Goltzman D, Hodsman AB

The Journal of clinical endocrinology and metabolism1 Jan 1995Cited by 24 (Europe PMC)

PMID7829640DOI10.1210/jcem.80.1.7829640PepBankPUB-07829640

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialPharmacokinetics
In healthy subjects, hPTH(1-34) and hPTHrP(1-34) had comparable distribution volumes.
In plain wordsIn healthy people, hPTH and hPTHrP had comparable distribution volumes.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeVolume of distribution
Study
n = 10
Comparator
hPTHrP-(1-34)
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10.7 nmol · intravenous bolusAs given in this study (human).
Source sentences
Summary
Measurements of plasma immunoreactive peptide indicated a comparable volume of distribution for each, but the apparent t1/2 (8.3 +/- 1.6 min) and plasma clearance (4.0 +/- 1.4 L/min) for hPTHrP were significantly (P < 0.05) accelerated compared to those of hPTH (t1/2, 10.2 +/- 0.5 min; clearance, 2.0 +/- 0.4 L/min).
1 context sentence(design, population, supporting numbers)
Summary · context
Ten healthy subjects [age, 25 +/- 9 (+/- SD) yr] received in random order either hPTH-(1-34) or hPTHrP-(1-34) given by bolus i.v. injections in a dose of 10.7 nmol.
Report a problemFND-0782964001
02HumanRandomized controlled trialPharmacokinetics
In healthy subjects, hPTH(1-34) had a longer apparent half-life than hPTHrP(1-34).
In plain wordsIn healthy people, hPTH remained in plasma longer than hPTHrP.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePlasma half-life
Study
n = 10
Comparator
hPTHrP-(1-34)
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10.7 nmol · intravenous bolusAs given in this study (human).
Measurements
Half-life
10.2 min
hPTH
Half-life
8.3 min
hPTHrP (comparator)
Source sentences
Summary
Measurements of plasma immunoreactive peptide indicated a comparable volume of distribution for each, but the apparent t1/2 (8.3 +/- 1.6 min) and plasma clearance (4.0 +/- 1.4 L/min) for hPTHrP were significantly (P < 0.05) accelerated compared to those of hPTH (t1/2, 10.2 +/- 0.5 min; clearance, 2.0 +/- 0.4 L/min).
1 context sentence(design, population, supporting numbers)
Summary · context
Ten healthy subjects [age, 25 +/- 9 (+/- SD) yr] received in random order either hPTH-(1-34) or hPTHrP-(1-34) given by bolus i.v. injections in a dose of 10.7 nmol.
Report a problemFND-0782964002
03HumanRandomized controlled trialPharmacokinetics
In healthy subjects, hPTH(1-34) had lower plasma clearance than hPTHrP(1-34).
In plain wordsIn healthy people, plasma cleared hPTH more slowly than hPTHrP.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePlasma clearance
Study
n = 10
Comparator
hPTHrP-(1-34)
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10.7 nmol · intravenous bolusAs given in this study (human).
Measurements
Clearance
2 L/min
hPTH
Clearance
4 L/min
hPTHrP (comparator)
Source sentences
Summary
Measurements of plasma immunoreactive peptide indicated a comparable volume of distribution for each, but the apparent t1/2 (8.3 +/- 1.6 min) and plasma clearance (4.0 +/- 1.4 L/min) for hPTHrP were significantly (P < 0.05) accelerated compared to those of hPTH (t1/2, 10.2 +/- 0.5 min; clearance, 2.0 +/- 0.4 L/min).
1 context sentence(design, population, supporting numbers)
Summary · context
Ten healthy subjects [age, 25 +/- 9 (+/- SD) yr] received in random order either hPTH-(1-34) or hPTHrP-(1-34) given by bolus i.v. injections in a dose of 10.7 nmol.
Report a problemFND-0782964003
04HumanRandomized controlled trialActivity measurement
In healthy subjects, hPTH(1-34) produced higher peak plasma cAMP than hPTHrP(1-34).
In plain wordsIn healthy people, hPTH produced higher peak plasma cAMP than hPTHrP.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePeak plasma cAMP
Study
n = 10
Comparator
hPTHrP-(1-34)
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
10.7 nmol · intravenous bolusAs given in this study (human).
Measurements
Peak plasma cAMP
190 pmol/L
hPTH-(1-34)
Peak plasma cAMP
29.5 pmol/L
hPTHrP-(1-34)
Source sentences
Summary
Peak plasma cAMP levels were 9-fold lower in response to hPTHrP (29.5 +/- 19 vs. 190 +/- 63 pmol/L; P < 0.01), and increases in urinary cAMP excretion were 5-fold lower (2.1 +/- 1.1 vs. 11.2 +/- 3.7 nmol/mmol creatinine; P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Ten healthy subjects [age, 25 +/- 9 (+/- SD) yr] received in random order either hPTH-(1-34) or hPTHrP-(1-34) given by bolus i.v. injections in a dose of 10.7 nmol.
Report a problemFND-0782964004
05HumanRandomized controlled trialActivity measurement
In healthy subjects, hPTH(1-34) produced a greater urinary cAMP increase than hPTHrP(1-34).
In plain wordsIn healthy people, hPTH increased urinary cAMP more than hPTHrP.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUrinary cAMP response
Study
n = 10
Comparator
hPTHrP-(1-34)
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
10.7 nmol · intravenous bolusAs given in this study (human).
Measurements
Urinary cAMP excretion increase
11.2 nmol/mmol creatinine
hPTH-(1-34)
Urinary cAMP excretion increase
2.1 nmol/mmol creatinine
hPTHrP-(1-34)
Source sentences
Summary
Peak plasma cAMP levels were 9-fold lower in response to hPTHrP (29.5 +/- 19 vs. 190 +/- 63 pmol/L; P < 0.01), and increases in urinary cAMP excretion were 5-fold lower (2.1 +/- 1.1 vs. 11.2 +/- 3.7 nmol/mmol creatinine; P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Ten healthy subjects [age, 25 +/- 9 (+/- SD) yr] received in random order either hPTH-(1-34) or hPTHrP-(1-34) given by bolus i.v. injections in a dose of 10.7 nmol.
Report a problemFND-0782964005
06HumanRandomized controlled trialActivity measurement
In healthy subjects, urinary phosphate excretion did not differ materially between hPTH(1-34) and hPTHrP(1-34).
In plain wordsIn healthy people, urinary phosphate excretion showed no major difference between hPTH and hPTHrP.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeUrinary phosphate excretion
Study
n = 10
Comparator
hPTHrP-(1-34)
Outcome group
Kidney function · Kidney and urinary
Studied dose
10.7 nmol · intravenous bolusAs given in this study (human).
Source sentences
Summary
No major differences were observed in the urinary excretion of phosphate, calcium, or sodium between the two peptides.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten healthy subjects [age, 25 +/- 9 (+/- SD) yr] received in random order either hPTH-(1-34) or hPTHrP-(1-34) given by bolus i.v. injections in a dose of 10.7 nmol.
Report a problemFND-0782964006
07HumanRandomized controlled trialActivity measurement
In healthy subjects, urinary calcium excretion did not differ materially between hPTH(1-34) and hPTHrP(1-34).
In plain wordsIn healthy people, urinary calcium excretion showed no major difference between hPTH and hPTHrP.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeUrinary calcium excretion
Study
n = 10
Comparator
hPTHrP-(1-34)
Outcome group
Kidney function · Kidney and urinary
Studied dose
10.7 nmol · intravenous bolusAs given in this study (human).
Source sentences
Summary
No major differences were observed in the urinary excretion of phosphate, calcium, or sodium between the two peptides.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten healthy subjects [age, 25 +/- 9 (+/- SD) yr] received in random order either hPTH-(1-34) or hPTHrP-(1-34) given by bolus i.v. injections in a dose of 10.7 nmol.
Report a problemFND-0782964007
08HumanRandomized controlled trialActivity measurement
In healthy subjects, urinary sodium excretion did not differ materially between hPTH(1-34) and hPTHrP(1-34).
In plain wordsIn healthy people, urinary sodium excretion showed no major difference between hPTH and hPTHrP.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeUrinary sodium excretion
Study
n = 10
Comparator
hPTHrP-(1-34)
Outcome group
Kidney function · Kidney and urinary
Studied dose
10.7 nmol · intravenous bolusAs given in this study (human).
Source sentences
Summary
No major differences were observed in the urinary excretion of phosphate, calcium, or sodium between the two peptides.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten healthy subjects [age, 25 +/- 9 (+/- SD) yr] received in random order either hPTH-(1-34) or hPTHrP-(1-34) given by bolus i.v. injections in a dose of 10.7 nmol.
Report a problemFND-0782964008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.